Explore

Trendline Trendline
Caribou Biosciences Advances CRISPR Gene Editing Trials for Cancer Therapies

Caribou Biosciences Advances CRISPR Gene Editing Trials for Cancer Therapies

Caribou Biosciences Advances CRISPR Gene Editing Trials for Cancer Therapies
Trendline Trendline
Novartis Stock Poised for Bullish Reversal Amid Strong Market Performance

Novartis Stock Poised for Bullish Reversal Amid Strong Market Performance

Novartis Stock Poised for Bullish Reversal Amid Strong Market Performance
Trendline Trendline
Biotechnology Companies Invest in Base Editing to Enhance Genetic Disorder Treatments

Biotechnology Companies Invest in Base Editing to Enhance Genetic Disorder Treatments

Biotechnology Companies Invest in Base Editing to Enhance Genetic Disorder Treatments
Trendline Trendline
Ambiq Micro Expands in Asia Pacific with Singapore Exchange Listing

Ambiq Micro Expands in Asia Pacific with Singapore Exchange Listing

Ambiq Micro Expands in Asia Pacific with Singapore Exchange Listing
Trendline Trendline
Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development

Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development

Claris Biotherapeutics Secures $118 Million for Eye Disease Treatment Development
Trendline Trendline
Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update
Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio
Trendline Trendline
Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments

Oak Hill Bio and RACC Announce Merger to Advance Rare Disease Treatments
Trendline Trendline
Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets
Trendline Trendline
Curtiss-Wright Corporation Prepares for Q2 2026 Earnings Report Amid Industry Anticipation

Curtiss-Wright Corporation Prepares for Q2 2026 Earnings Report Amid Industry Anticipation

Curtiss-Wright Corporation Prepares for Q2 2026 Earnings Report Amid Industry Anticipation
Trendline Trendline
Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA
Trendline Trendline
Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments